Pharmather announces a new development agreement with CCBIO to create a proprietary wearable ketamine delivery solution for mental health.
Exploring the companies and themes that make up this emerging and exciting new sector
Why Is The Psychedelic Drug Industry Suddenly In Favor With Global Power Players?
The psychedelic drug industry has suddenly attracted the attention of the most influential "power players" on the planet. It's great news for the industry, but...
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
Compass Pathways announces the release of the largest randomized, controlled, double-blind study ever completed on psilocybin-assisted therapy.
U.K. Member of Parliament Crispin Blunt To Inaugurate Psilocybin Cultivation Facility At Optimi Health Grand Opening
Optimi Health announces that UK MP, Cristin Blunt will be appearing as a guest speaker at the grand opening ceremony for its Princeton, B.C. cultivation facility.
Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007
Seelos Therapeutics announces receiving its Notice of Allowance from the USPTO for SLS-007 as a method of treatment.
Awakn Life Sciences Completes World's First Ketamine Treatment Study for a Range of Behavioral Addictions
Awakn Life Sciences announce promising results from the first study of ketamine-assisted therapy for behavioral addictions, and will be initiating a larger follow-up study.
Mydecine Announces Size of Previously Announced Overnight Marketed Public Offering of Units
Mydecine Innovations Group announces the issuance of 3,478,260 units at a unit price of CAD$1.15, for gross proceeds of up to CAD$4 million.
Novamind Launches Group Psychedelic Treatment for Frontline Workers
Novamind announces the full-scale launch of Frontline KAP, group-based ketamine-assisted therapy for frontline healthcare workers suffering from burnout/stress/trauma, at select clinic locations.
Albert Labs Granted Health Canada Licence
Albert Labs announces the receipt of its Dealer's License from Health Canada, allowing possession/sale/delivery of psilocybin and other controlled substances.
MindMed Announces At-The-Market Offering
MindMed announces an at-the-market financing with a prospectus authorizing share sales of up to $100,000,000. Not open to Canadian investors.
Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022
Cybin Inc announces that it will take part in the NYSE's "morning bell" ceremony for the May 18th trading session.
Incannex Announces Positive Pre-IND Meeting with U.S. FDA for IHL-42X for Obstructive Sleep Apnoea
Incannex Healthcare announces a positive Pre-Investigational New Drug Application meeting with the FDA concerning IHL-42X, a compound for treating sleep apnoea.